Osteoarthritis is the most common musculoskeletal disease and the leading cause of disability globally. Here, we performed a genome-wide association study for osteoarthritis (77,052 cases and 378,169 controls), analyzing four phenotypes: knee osteoarthritis, hip osteoarthritis, knee and/or hip osteoarthritis, and any osteoarthritis. We discovered 64 signals, 52 of them novel, more than doubling the number of established disease loci. Six signals fine-mapped to a single variant. We identified putative effector genes by integrating expression quantitative trait loci (eQTL) colocalization, finemapping, and human rare-disease, animal-model, and osteoarthritis tissue expression data. We found enrichment for genes underlying monogenic forms of bone development diseases, and for the collagen formation and extracellular matrix organization biological pathways. Ten of the likely effector genes, including TGFB1 (transforming growth factor beta 1), FGF18 (fibroblast growth factor 18), CTSK (cathepsin K), and IL11 (interleukin 11), have therapeutics approved or in clinical trials, with mechanisms of action supportive of evaluation for efficacy in osteoarthritis.
Osteoarthritis affects 40% of individuals over the age of 70 (ref. 1 ) and is a major cause of pain, comorbidity, and mortality 2 . Ten million people in the UK alone suffer from osteoarthritis, with a total indirect cost to the economy of £14.8 billion per annum 2 . Disease management targets the main symptom (pain) and culminates in joint replacement surgery (1.76 million per year in the EU) with variable outcomes 3 . There is a clear and urgent need to translate genomic evidence into druggable mechanisms of disease etiology and progression, to support the development of disease-modifying therapies for osteoarthritis.
Here, we leveraged the UK Biobank and Arthritis Research UK Osteoarthritis Genetics (arcOGEN) resources to perform a genome-wide meta-analysis for osteoarthritis across approximately 17.5 million single-nucleotide variants in up to 455,221 individuals ( Supplementary Fig. 1 ). We identified 65 genome-wide-significant variants at 64 loci (P ≤ 3 × 10 −8 Online Methods and Supplementary Table 1 ), 52 of which are novel, thus increasing the number of established loci from 34 (ref. 4 ) to 86: 24 novel signals for osteoarthritis at any site (77,052 cases), 15 for hip osteoarthritis (15,704 cases), 7 for knee osteoarthritis (24,955 cases), and 6 for osteoarthritis of the hip and/or knee (39, 427 Tables 2 and 3 ). We found that 25 of 34 previously reported loci showed association (P < 0.05) with at least one of the four osteoarthritis traits evaluated ( Supplementary Table 4 ).
To identify putative effector genes at the 64 genome-wide-significant regions, we integrated results from several strands of investigation, including transcriptomic and proteomic characterization of primary tissue from patients with osteoarthritis undergoing joint replacement surgery, coupled with statistical finemapping, annotation of predicted consequences of variants in the credible sets, eQTL colocalization, and relevant rare-human-disease and animal-model evidence (Online Methods and Supplementary Tables 5 and 6 ). We observed evidence of colocalization in at least one tissue for 49 out of the 64 loci, 44 of which were at newly associated osteoarthritis signals (Supplementary Table 7 and Supplementary Fig. 7 ). Using MetaXcan, we identified 11 genes with additional evidence of colocalization at loci not reaching genome-wide significance in single-nucleotide variant analyses ( Supplementary Fig. 8 and Supplementary Tables 8 and 9 ).
Pathway analyses (Online Methods and Supplementary Note) identified 64 biological processes associated with osteoarthritis, of which 46 were bone-, cartilage-, and chondrocyte-morphology related (Supplementary Table 10 ). The collagen formation and extracellular matrix organization biological pathways were Letters NaTure GeNeTicS Letters NaTure GeNeTicS consistently identified by different pathway analysis methods. Genome-wide linkage disequilibrium (LD)-score regression analysis 5, 6 unveiled significant correlations between osteoarthritis and traits within the obesity, cognition, smoking, bone mineral density, and reproductive trait categories ( Fig. 1 and Supplementary Tables  11 and 12 ). Mendelian randomization analyses (Online Methods) supported a role for higher body mass index (BMI) and adiposity in osteoarthritis risk and identified a potential protective effect of low-density lipoprotein (LDL) cholesterol and of higher levels of education against osteoarthritis (Supplementary Tables 13-15 and Supplementary Note). Two of the BMI loci (SLC39A8 and FTO) showed genome-wide-significant associations with osteoarthritis, with SLC39A8 showing much larger effects on osteoarthritis than expected given the BMI-raising effects ( Supplementary Fig. 9 ). The apparent causal associations of knee pain with osteoarthritis ( Supplementary Tables 13 and 16 ) were potentially attributable to reverse causality (Supplementary Note). We estimated the proportion of the total narrow sense heritability explained by osteoarthritis loci to be 14.7% for knee osteoarthritis, 51.9% for hip osteoarthritis, 24.2% for osteoarthritis of the hip and/or knee, and 22.5% of osteoarthritis at any site ( Supplementary Table 17 ). We did not find evidence for a role of low-frequency or rare variation of large effect in osteoarthritis susceptibility, and had limited power to detect smaller effects at lower-frequency variants (Fig. 2 ). In the future, meta-analyses of osteoarthritis studies in global populations will help to further deconvolute the genetic underpinning of this disabling disease. We used a combination of conditional analyses 7 followed by asymptotic Bayes-factor fine-mapping 8 (Online Methods) of conditionally distinct association signals to identify causal variants. In six of the novel loci, a single variant could be postulated as causal with more than 95% posterior probability: missense variants in SLC39A8, IL11, and ANAPC4 (rs13107325, rs4252548, and rs34811474, respectively), rs75621460 near TGFB1, rs547116051 near MAPT, and rs528981060 near SCUBE1 ( Supplementary Table  18 and Supplementary Note). We observed strong enrichment for genes known to cause monogenic bone development diseases and forms of early-onset osteoarthritis, in the vicinity of osteoarthritis signals (odds ratio (OR) 8.87, P = 1.8 × 10 −4 , and OR 8.83, P = 8 × 10 −3 , respectively) ( Supplementary Tables 19 and 20) . This finding highlights bone development as an important physiological process in osteoarthritis etiology. Several genes identified as likely to be causal in our study have also been linked to osteoarthritis aetiology in animal models. In eight out of the ten cases in which we were able to unequivocally define directionality of association, we observed concordance between our results and those from animal models (that is, that lower expression or loss-of-function mutations increased osteoarthritis risk both in humans and in animal models) (Supplementary Table 21 ). Some of these genes encode structural bone or cartilage proteins (COL11A1 and COL11A2) or have a critical role in bone or cartilage development (FGFR3 and GDF5). These consistent observations in human and animal models provide compelling evidence for a causal role of these genes in osteoarthritis and point to an agonist strategy as the desired mechanism of action for new osteoarthritis drugs targeting these eight genes.
Ten genes have a therapeutic approved or in clinical trials (Table 2) , with mechanisms of action that are not inconsistent with potential for efficacy in osteoarthritis, on the basis of eQTL, functional genomics, rare-disease, and animal-model data. Four of these genes, TGFB1, GDF5, FGF18, and CTSK, currently have therapeutics in clinical development for osteoarthritis or cartilage regeneration indications. Of these, only GDF5 has been reported to be genetically associated with osteoarthritis susceptibility 9 . Two of the genes, IL11 and DPEP1, have approved therapeutics for unrelated indications, thus opening the possibility for repositioning.
rs4252548 (hip osteoarthritis, posterior probability of causality (PPC) 0.99) is a predicted deleterious missense variant (p.Arg112His) in IL11 (interleukin-11) that is associated with increased risk of hip osteoarthritis. Using RNA sequencing (Online Methods), we found that IL11 showed increased expression in EA/NEA, effect allele/noneffect allele; i2, I² statistic describing the percentage of variation across studies that is due to heterogeneity rather than chance; OA, osteoarthritis; OA_hip, hip osteoarthritis; OA_knee, knee osteoarthritis; OA_kneehip, knee and/or hip osteoarthritis; OR_95CI, lower bound of the 95%-credible interval of the OR, upper bound of the 95%-credible interval of the OR; PV, P value (two sided); q_pv, P value of Cochran's Q measure of heterogeneity; trait, osteoarthritis trait most significantly associated with variant in the meta-analysis stage; other traits, other osteoarthritis traits with genome-wide-significant association following meta-analysis; WEAF, weighted effect allele frequency between UK Biobank and arcOGEN. Letters NaTure GeNeTicS degraded than intact cartilage (log 2 (fold change) = 0.787, false discovery rate (FDR) = 4.82 × 10 −3 ). This cytokine is a potent stimulator of bone formation 10 , is required for normal bone turnover 11 , and has been found to be upregulated in osteoarthritis knee tissue and to be associated with disease progression 12 . The rs4252548 osteoarthritis risk allele is also associated with decreased adult height 13 . A recombinant human IL11 molecule (NEUMEGA) with three-fold-enhanced affinity for IL11RA, as compared with IL11 (ref. 14 ), is approved for the treatment of chemotherapy-induced thrombocytopenia ( Table 2 ). The probable effects of increased IL11 signaling in osteoarthritis joints are currently not well understood, and it is worth evaluating this therapeutic for potential efficacy in disease models. The rs1126464 (osteoarthritis, PPC 0.89) locus index signal is a missense variant (p.Glu351Gln) in DPEP1 that is predicted to be tolerated. DPEP1 hydrolyses a wide range of dipeptides and is implicated in the renal metabolism of glutathione and its conjugates. A DPEP1 inhibitor, cilastatin, is approved and used in combination with the antibiotic imipenem, to protect it from dehydropeptidase and prolong its antibacterial effect 15 . We suggest investigating the effects of cilastatin in osteoarthritis models to determine whether this has potential as a therapeutic or whether an agonist may be efficacious.
rs75621460 (hip and/or knee osteoarthritis, single variant in the 95%-credible set) is an intergenic variant residing downstream of CCDC97 and TGFB1 (Table 1 and Supplementary Table 3 ), and it is colocalized with a TGFB1 eQTL in sun-exposed skin (GTEx) (Supplementary Table 6 ). Mutations in TGFB1 cause Camurati-Engelmann disease, which is characterized by diaphyseal dysplasia with thickening and fluctuating bone volume giving rise to bone pain, muscle weakness, gait issues, and tiredness 16,17 . TGFB1 has a critical role in skeletal development and adult bone homeostasis 18 , including bone remodeling 19 , osteoclast and osteoblast differentiation 20,21 , and chondrogenesis 22 . INVOSSA, a TGFB1 cell and gene therapy in chondrocytes, is associated with significant improvements in function and pain in patients with knee osteoarthritis 23 .
The importance of TGFB1 signaling in osteoarthritis is supported by significant enrichment for TGFβ -signaling-pathway genes ( Supplementary table 10 ), including LTBP1, LTBP3, SMAD3, and RUNX2. LTBP1, at the novel rs4671010 locus, encodes latent-transforming growth factor β -binding protein 1, which interacts directly with TGFB1; is involved in the assembly, 
Fig. 1 | Genetic correlations between osteoarthritis and other traits and diseases.
Genetic correlations (rg) between osteoarthritis and other publicly available GWAS results, based on LD score regression as implemented in LDHub. The diagram shows traits with significant correlation (P < 0.05) and 95% confidence intervals across all osteoarthritis definitions. The red outlines of the bars denote negative correlations, and the blue outlines denote positive correlations. The upper-right legend shows the categories of the traits. OA, osteoarthritis; OA_hip, hip osteoarthritis; OA_knee, knee osteoarthritis; OA_ kneehip, knee and/or hip osteoarthritis. Lumbar spine bone mineral density 1 and 2 relate to two different published studies.
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NaTure GeNeTicS secretion, and targeting of TGFB1 to sites at which it is stored and/or activated; and may contribute to controlling the activity of TGFB1 (ref. 24 ). LTBP3 (novel locus rs10896015) encodes latent-transforming growth factor β -binding protein 3, which interacts directly with and activates TGFB1 in the early proliferative phase of osteogenic differentiation 25 . SMAD3 (known locus rs12901372) encodes a transcriptional modulator that has a critical role in chondrogenic differentiation and regulates TGFB1 expression 26 ; and the TGFB1-SMAD3 pathway regulates the expression of miR-140 in osteoarthritis 27 . The directionality of the colocalized eQTL and animal-model data suggests that agonism or upregulation of LTBP1, LTBP3, and SMAD3 may be therapeutic for osteoarthritis ( Supplementary Table 21 ). RUNX2 (known locus rs2064630) encodes a transcription factor essential for osteoblast differentiation and chondrocyte maturation 28 , and it is downregulated by TGFB1 (ref. 29 ). Given the genetic and biological support for the importance of TGFB1 in osteoarthritis etiology and treatment, there may be a scope for the development of simpler osteoarthritis therapeutics that target this mechanism, such as a small molecule or antibody.
Although it is not a current drug target, the novel SLC39A8 association is noteworthy. rs13107325 (osteoarthritis, PPC 0.99) is a missense variant that is located in SLC39A8 and demonstrates significantly increased expression in degraded compared with intact articular cartilage (log 2 (fold change) = 0.522, FDR = 5.80 × 10 −5 ) ( Table 1 and Supplementary Table 2 ), a finding consistent with previously reported elevated levels of SLC39A8 in osteoarthritis, as compared with healthy chondrocytes 30,31 . rs13107325 is also associated with obesity 32 , hypertension 33 , Crohn's disease, and altered microbiome composition 34 . SLC39A8 encodes a zinc transporter, ZIP8, that functions in the cellular import of zinc at the onset of inflammation. Suppression of SLC39A8 has been shown to decrease cartilage degradation in osteoarthritis animal models 30 . The zinc-SLC39A8-MTF1 axis has been proposed to be an essential catabolic regulator of osteoarthritis pathogenesis 31 .
In this study, we more than doubled the number of known osteoarthritis risk loci, as supported by integrated eQTL colocalization, fine-mapping, Mendelian bone disease, animal-model and differential osteoarthritis joint expression data, to reveal putative effector genes. In addition to identifying chondrocyte and osteoblast biological mechanisms implicated in osteoarthritis susceptibility, we revealed biological mechanisms that represent attractive targets for osteoarthritis drug discovery, and we highlighted approved therapeutics that represent viable considerations for repositioning as osteoarthritis therapies. We anticipate that this advance in basic understanding of osteoarthritis risk factors and mechanisms will stimulate the evaluation of novel drug targets for osteoarthritis. 
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Methods
Studies. UK Biobank. UK Biobank is a cohort of 500,000 participants 40-69 years of age recruited between 2006 and 2010 in 22 assessment centres throughout the UK 35 . The assessment visit included electronic signed consent, a self-completed touch-screen questionnaire, a brief computer-assisted interview, physical and functional measures, and collection of biological samples and genetic data. This work was based on the third UK Biobank release, which includes the full set of the 500,000 genotypes imputed on the Haplotype Reference Consortium 36 and the 1000 Genomes Consortium 37 . The case and control definition, genotyping, imputation, and association testing are described in the Supplementary Note. arcOGEN cases. arcOGEN is a collection of unrelated, UK-based individuals of European ancestry with knee and/or hip osteoarthritis from the arcOGEN Consortium 9, 38 . Cases were ascertained on the basis of clinical evidence of disease to a level requiring joint replacement or radiographic evidence of disease (Kellgren-Lawrence grade ≥ 2). The arcOGEN study was ethically approved by appropriate review committees, and the prospective collections were approved by the National Research Ethics Service in the United Kingdom. All subjects in this study provided written, informed consent.
United Kingdom Household Longitudinal Study (UKHLS) controls.
The UKHLS, also known as Understanding Society, is a longitudinal panel survey of 40,000 UK households (from England, Scotland, Wales, and Northern Ireland) representative of the UK population. Participants have been surveyed annually since 2009 and contribute information relating to their socioeconomic circumstances, attitudes, and behaviors via a computer-assisted interview. The study includes phenotypic data for a representative sample of participants for a wide range of social and economic indicators as well as a biological sample collection encompassing biometric, physiological, biochemical, and hematological measurements, and selfreported medical history and medication use. The UKHLS has been approved by the University of Essex Ethics Committee, and informed consent was obtained from every participant. The genotyping, imputation, and association testing were carried out as described previously 9, 39, 40 (Supplementary Note) .
Meta-analysis.
We carried out meta-analysis of the UK Biobank and arcOGEN data sets by using fixed-effects inverse-variance-weighted meta-analysis in METAL 41 . We performed meta-analyses across osteoarthritis definitions by using summary statistics from the UK Biobank and arcOGEN cohorts, and we defined genome-wide significance on the basis of the meta-analysis combined P value, as outlined below.
Significance threshold. The osteoarthritis traits analysed in this study are highly correlated. To calculate M_eff (the effective number of independent traits), we estimated the genetic correlation matrix between the four osteoarthritis traits (Supplementary Table 1 ) by using LDscore 42 with genome-wide summary statistics of common-frequency variants in the UK Biobank data set. We then calculated M_eff from the eigenvalues λ_i of the correlation matrix 43 :
For the M = 4 osteoarthritis phenotypes in this study, M_eff = 1.6046. We therefore used P ≤ 3 × 10 −8 as the threshold corrected for the effective number of traits to report genome-wide significance.
Statistical independence.
To define independent signals within a genome-wide association study (GWAS), we performed physical clumping by using a simple iterative procedure. We ranked all variants that reached a P-value threshold according to their P value. The variant with the smallest P value was considered the index variant of that signal, and any variants within a 1 Mb region either side of that index variant that reached the predefined P-value threshold were clumped with that variant. We repeated the procedure until no more variants that reached the predefined P value threshold existed that had not been assigned to a physical clump. To test that the index variants defined by this procedure were statistically independent, we performed an approximate stepwise model-selection procedure, as implemented by COJO in GCTA 7 . An independent signal in a region was declared if its P value of association in the stepwise regression was less than 3 × 10 −8 . LD calculations were based on the full UK Biobank imputed set.
To define independent signals across the four osteoarthritis GWAS, we performed reciprocal approximate conditional analyses, as implemented by COJO in GCTA 7 , of each index variant of one GWAS conditioned on each index variant of the other GWAS. A signal between two GWAS was considered to be the same if the P value of an index variant of one GWAS conditioned on an index variant of the other GWAS was ≤ 10 -5 or a P-value difference between conditional and unconditional analysis of less than two orders of magnitude.
To investigate statistical independence between index variants from each GWAS and previously reported variants, we performed approximate conditional analysis, as implemented by COJO in GCTA 7 , of each index variant conditional on all previously reported variants within a 1-Mb region, each one at a time. The index variant was considered independent from a previously reported variant if it had a conditional P ≤ 10 −5 or a P-value difference between conditional and unconditional analysis of less than two orders of magnitude. Variants were classified as known (denoting either a previously reported variant or a variant for which the association signal disappeared after conditioning on the lead variant of a previously reported locus) or newly identified (denoting a variant that was conditionally independent of previously reported loci).
Fine-mapping. We constructed regions for fine-mapping by taking a window of 1 Mb either side of each index variant. Within each region, we performed an approximate stepwise model-selection procedure, as implemented by COJO in GCTA 7 , by using the meta-analysis summary statistics and LD calculations based on the UK Biobank cohort to determine the number of independent signals. We considered conditionally distinct signals as those for which the stepwise regression association reached genome-wide significance (P < 3.0 × 10 −8 ). We then performed single-SNP approximate association analyses conditional on the set of SNPs identified by the model-selection procedure, again using COJO, and we calculated Wakefield's asymptotic Bayes factors 8 (ABF). In particular, when there was a single causal variant in the region, ABF was based on the marginal summary statistics of the meta-analysis. When there were multiple causal variants in the region, for each signal we calculated a set of ABF, using the conditional summary statistics of the meta-analysis conditioned on all other signals. For each signal, we then calculated posterior probabilities of each variant being causal and a 95%-credible set, which contained the minimum set of variants that jointly had at least a 95% probability of including the causal variant. Because this number can be large, we focused on the variants in the 95%-credible set that had posterior PPC > 3% and also on any variants in the 95%-credible set with moderate or high consequence (irrespective of their PPC).
Genetic correlation analysis.
To better understand the degree to which genetic architecture is shared across osteoarthritis and other complex traits, LD-score regression 5 was performed as implemented in the LDHub pipeline 6 (URLs). We calculated the genome-wide genetic correlation between each of the osteoarthritis definitions and all available 832 human traits and diseases (accessed 15-18 June, 2018). Of these, 597 traits were available within the UK Biobank resource. In each analysis, all variants in the major histocompatibility complex (MHC) region on chromosome 6 (26-34 Mb) were removed, and only variants with rsIDs were included in the analyses, thus yielding 1203892-1204029 variants overlapping with LDHub. We used the Benjamini-Hochberg FDR and the effective number of independent traits tested for multiple testing correction. The level of significance was set at FDR-corrected P < 0.05.
Mendelian randomization.
We performed Mendelian randomization analyses by using the MR-Base platform 44 . We tested the bidirectional causal associations of each of the four osteoarthritis data sets with 991 exposures or outcomes in MR-Base. Statistical significance was considered for P < 6.3 × 10 −6 . To follow up on pain associations, we performed analyses of knee and hip pain as an outcome after excluding all individuals with self-reported or hospital-diagnosed osteoarthritis in the UK Biobank. All instruments were aggressively clumped before analysis (LD r 2 < 0.001) and inverse-variance-weighted (IVW), median-weighted, and MR-Egger analyses were performed for multivariant instruments, and Wald ratio estimators were used to assess causality for single-variant instruments.
Transcriptome-wide association. We used a gene-based approach, MetaXcan 45 , to test for associations between the osteoarthritis traits and predicted expression levels in 48 human tissues from GTEx V7 (ref. 46 ). MetaXcan leverages a set of reference individuals for whom both gene expression and genetic variation have been measured to impute the cis-genetic component of expression into a much larger set by using the elastic net model. It then correlates the imputed gene expression to the trait of interest and performs a transcriptome-wide association study to identify significant expression-trait associations. We used a conservative Bonferroni correction to account for the gene-tissue pairs (20,000 genes across 48 tissues), thus leading to a significance threshold of 5.20 × 10 −8 . To reduce the effect of LD confounding on the MetaXcan results, when different causal SNPs were affecting expression levels and the phenotypic trait in a GWAS, we estimated the probability of colocalization of each GWAS and eQTL signal in each significant MetaXcan result by using Coloc 47 (Supplementary Note, Supplementary Fig. 8 , and Supplementary Tables 8 and 9 ).
Colocalization analysis.
To assess whether the genome-wide-significant osteoarthritis signals colocalized with eQTL signals and therefore potentially shared a causal molecular mechanism, we used the Coloc method 47 , which uses asymptotic Bayes factors with summary statistics and regional LD structure to estimate five posterior probabilities: no association with either GWAS or eQTL (PP0), association with GWAS only (PP1), association with eQTL only (PP2), association with GWAS and eQTL but two independent SNPs (PP3), and association with GWAS and eQTL having one shared SNP (PP4). A large posterior probability for PP4 indicates support for a single variant affecting both GWAS and eQTL studies. For each of the GWAS signals, we defined a 100-kb region either Letters NaTure GeNeTicS side of the index variant and tested for colocalization within the entire cis region of any overlapping eQTLs (transcription start and end position of an eQTL gene plus and minus 1 Mb, as defined by GTEx) in 48 human tissues from GTEx v7 (ref. 46 ). A PP4 greater than or equal to 80% was considered evidence for colocalization (Supplementary Note and Supplementary Table 7) .
Most colocalization methods, such as Coloc, rely on the availability of genomewide eQTL results, which are not always readily available. For eQTL data sets with no publically available full summary statistics, we used an alternative approach that estimates the probability of colocalization by using published top eQTL signals. First, we estimated the credible sets for the eQTLs by using the probabilistic identification of causal SNPs (PICS) method 48 for each index SNP for each gene from 27 eQTL studies (Supplementary Table 6 ). PICS is a fine-mapping algorithm that assumes one causal signal tagged by a single index SNP per locus. For neutral SNPs (SNPs whose association signals are due to LD with the causal SNP), the strength of association scales linearly with the r 2 relationship or distance to the index SNP. Under this assumption, PICS can estimate the posterior probability of a given SNP being causal by using LD information from the 1000 Genomes database. Second, we generated PICs credible sets for osteoarthritis GWAS index SNPs. We then performed a colocalization analysis of the osteoarthritis GWAS and eQTL PICs credible sets by using an adapted Coloc method 49 . Given that PICS calculates the posterior probabilities for each SNP in the credible set, we bypassed the need for calculating the Bayes Factors by using Wakefield's approximate Bayes factor method, which is reliant on full summary statistics. Colocalizations with a posterior probability greater than 0.8 were considered positive. This method was benchmarked on other GWAS datasets, and we found the false-positive rate to be no higher than that with the standard Coloc package.
We observed evidence of colocalization in at least one tissue for 50 out of our 64 loci by using any of the three methods (MetaXcan, Coloc, or Piccolo), 41 of which were at newly associated osteoarthritis signals (Supplementary Table 7 ). MetaXcan alone identified 119 genes, Coloc identified 113 genes, and Piccolo identified 58 genes, whereas the overlap of all three methods implicated 20 genes (TGFA, ILF3, CSK, CYP1A1, ULK3, CHMP1A, TSKU, SUPT3H, GNL3, NT5DC2, LMX1B, SMAD3, MLXIP, COLGALT2, FAM89B, UQCC1, NFAT5, ALDH1A2, FAM53A, and FGFR3; Supplementary Fig. 7 ).
Heritability estimation. To investigate the narrow sense heritability for the four osteoarthritis disease definitions, we ran LDscore 42 , which uses summary statistics at common-frequency variants genome wide (independently of P-value thresholds) and LD estimates between variants, while accounting for sample overlap. To calculate the population prevalence in the UK (65 million people), we consulted Arthritis Research UK figures: 8.75 million people have symptomatic osteoarthritis, and 2.46 and 4.11 million people have osteoarthritis of the hip and the knee, respectively. We assumed that 2.46 + 4.11 million people have osteoarthritis of the hip and/or the knee. We estimated the phenotypic variance explained by the 99 previously and newly reported variants that reached genomewide significance in the meta-analysis between UK Biobank and arcOGEN, as a function of allele frequency ( Fig. 2 and Supplementary Table 17 ). The phenotypic variance explained by a variant is
, where ln(OR) is the natural logarithm of the OR of the variant in the meta-analysis, and EAF is its weighted effect allele frequency across UK Biobank and arcOGEN. Variants associated with hip osteoarthritis tend to have larger effect size estimates and hence explain more of the phenotypic variability ( Fig. 2 and Supplementary Table  17 ). The hip osteoarthritis data set is the smallest in both the UK Biobank and arcOGEN cohorts (18% and 59% fewer cases than for knee osteoarthritis and osteoarthritis at any joint in the UK Biobank, respectively).
Pathway analysis.
We performed gene-set analyses for each of the osteoarthritis phenotypes separately, using MAGMA v1.06 (ref. 50 ). We mapped variants to 19,427 protein-coding genes (NCBI 37.3), including a 10-kb window on either side of the gene. We then computed gene P values based on individual variant association P values. We used the 'snp-wise = mean' model, which calculates the mean of the chi-square statistic among the single variant P values in each gene, and applied default MAGMA QC steps. Genotype data of 10,000 individuals (subset of self-reported plus hospital-diagnosed osteoarthritis at any site analysis), were used to calculate LD (as measured by r 2 ). We carried out a one-sided competitive gene-set analysis for each phenotype, implemented as a linear regression model on a gene data matrix created internally from the gene-based results. In brief, this process converts the gene-based P values to Z scores, and tests whether the mean association with the phenotype of genes in the gene set is greater than that of all other genes. We used the Kyoto Encyclopedia of Genes and Reactome (accessed through MSigDB113 (version 5.2) on 23 January, 2017). We also downloaded Gene Ontology (GO) biological process and molecular-function gene annotations from Ensembl (version 87). We used annotations with the following evidence codes: inferred from mutant phenotype (IMP); inferred from physical interaction (IPI); inferred from direct assay (IDA); nferred from expressionpattern (IEP); and traceable author statement (TAS). KEGG and Reactome, and GO annotations were analysed separately, and only pathways that contained between 20 and 200 genes were included (594 for KEGG and Reactome, 619 for GO). We used MAGMA's built-in permutation method (k = 10,000 permutations) to produce corrected competitive P values with a familywise error rate of 5%. We then further adjusted these corrected competitive P values for the effective number of independent traits tested (1.6046).
We also performed gene-set enrichment analysis by using DEPICT (URLs) and PASCAL (URLs). DEPICT version 1 rel194 was downloaded from GitHub (URLs) on 14 June, 2018. We ran DEPICT separately in each of the four osteoarthritis definitions for the variants with a meta-analysis P < 1 × 10 −5 . In brief, DEPICT first clumped the variants with P < 1 × 10 −5 , using 500-kb flanking regions as a physical distance threshold and an r 2 > 0.1 with PLINK 51 to obtain lists of independent SNPs, thus resulting in 864 clumps. Variants within the MHC region on chromosome 6 were excluded. DEPICT analyses were conducted by using the default settings: 50 repetitions to compute FDR and 500 permutations based on 500 null GWAS to compute P values adjusted for gene length. All 14,461 available reconstituted gene sets were used, representing a wide spectrum of biological and mouse phenotypic annotations. We also used the method implemented in PASCAL to perform geneset enrichment analysis accounting for LD structure in the genome, particularly of highly correlated chromosomal regions containing multiple genes that can negatively affect the results of the analysis. In this approach, variants were first mapped to genes, including a 10-kb window on either side of the gene. We then computed gene scores by aggregating the single-marker association values with the LD structure. Finally, the scores of genes that belonged to the same pathways (that is, gene sets) were used to compute pathway scores and determine the statistical significance of the association between the pathway and each of the osteoarthritis phenotypes. Here, we used exactly the same pathways of the MAGMA analysis. The gene and the pathway scores were calculated by using the sum gene score and the chi-square approach, respectively, as implemented in PASCAL. All pathway P values obtained by either software were adjusted for multiple testing correction by using the FDR and the effective number of independent traits. The level of significance was set at FDR-corrected P < 0.05.
Monogenic enrichment analysis.
We compiled a systematic list of genes causing bone phenotypes in humans by scanning the STOPGAP database 52 , which uses OMIM (URLs) and Orphanet (URLs) to define genes underlying monogenic and Mendelian diseases. We selected all genes causing monogenic diseases and annotated with MeSH terms (medical subject headings) related to bone, cartilage, or joint disease, including 'bone disease, developmental' , 'osteochondrodysplasias' , 'osteogenesis imperfecta' , 'osteoporosis' , 'osteopetrosis' , 'arthritis, juvenile' , and 'arthrogryposis' . Other bone-, cartilage-, or joint-related mesh terms linked to fewer than ten genes in the STOPGAP database were excluded from the analysis. In addition, we selected a list of well-validated genes underlying syndromic or nonsyndromic forms of early-onset osteoarthritis (EO-OA) from a review (ref. 53 ). For enrichment analysis, genes residing within 500 kb of each index variant identified in our GWAS were considered osteoarthritis loci, and the rest of the genes in the genome associated with any mesh term in STOPGAP were considered nonosteoarthritis loci. We built a 2 × 2 table by counting the number of genes annotated to each of the above-mentioned MeSH terms among osteoarthritis and nonosteoarthritis loci. We assessed evidence for enrichment by using Fisher's exact test.
Transcriptomic and proteomic analyses. Patients and samples. We collected cartilage samples from 38 patients undergoing total joint replacement surgery: 12 knee osteoarthritis patients (cohort 1; 2 women, 10 men, aged 50-88 years); knee osteoarthritis patients (cohort 2; 12 women 5 men, aged 54-82 years); and 9 hip osteoarthritis patients (cohort 3; 6 women, 3 men, aged 44-84 years). We collected matched intact and degraded cartilage samples from each patient. Cartilage was separated from bone, and chondrocytes were extracted from each sample. From each isolated chondrocyte sample, we extracted DNA, RNA, and protein. All patients provided full written informed consent before participation. The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an Institutional Review Board (IRB)-or Ethics Committee (EC)-approved protocol. All sample collection, DNA, RNA, and protein analysis steps are described in detail in ref. 54 .
Proteomics and RNA sequencing. Proteomics analysis was performed on intact and degraded cartilage samples from 24 individuals (15 from cohort 2, 9 from cohort 3). We performed gene expression analysis on samples from all 38 patients (Supplementary Note).
Animal-model data. The presence of abnormal skeletal phenotypes in mice was evaluated for all genes within 500 kb of an osteoarthritis index variant and extracted from Open Targets 55 . This platform integrates all abnormal phenotype annotations for mutations in mouse genes reported in the literature and curated in MGI (URLs). Given the list of genes located less than 1 Mb away from the 64 genome-wide-significant signals for osteoarthritis, abnormal skeletal system phenotypes from mutant mice were extracted systematically for all mouse orthologs of the human genes by using the programmatic interface of the Open Targets platform ( Supplementary Table 21 ). For example, mutant mice homozygous for a targeted mutation of Smad3 (the ortholog of human SMAD family member 3) developed degenerative joint disease through progressive loss 1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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